Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in refractory thyroid cancer
NCT03199677Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jul 2017
- Primary completion
- Jun 2018
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib in thyroid cancer, sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT03199677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03199677.